Le Lézard
Classified in: Ebola virus, Health
Subject: SVY

Tissue and Hygiene Products Market Analysis, Trends, and Forecasts, 2025 - Global Market is Projected to Grow by $14 Billion


DUBLIN, Nov. 22, 2019 /PRNewswire/ -- The "Tissue and Hygiene Products - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The Tissue and Hygiene Products market worldwide is projected to grow by US$14 Billion, driven by a compounded growth of 3.7%.

Tissue Products, one of the segments analyzed and sized in this study, displays the potential to grow at over 3.5%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$24.4 Billion by the year 2025, Tissue Products will bring in healthy gains adding significant momentum to global growth.

Representing the developed world, the United States will maintain a 2.9% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$514.6 Million to the region's size and clout in the next 5 to 6 years. Over US$407.8 Million worth of projected demand in the region will come from the rest of the European markets. In Japan, Tissue Products will reach a market size of US$1.5 Billion by the close of the analysis period.

As the world's second largest economy and the new game changer in global markets, China exhibits the potential to grow at 5.8% over the next couple of years and add approximately US$3.9 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders.

Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio.

Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include:

For more information about this report visit https://www.researchandmarkets.com/r/tajpqw

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 00:05
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:05
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...

at 00:00
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...

24 avr 2024
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

24 avr 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...



News published on and distributed by: